Policy | August 04, 2021
India Initiates anti dumping probe against import of ATS-8 from China
Arch Pharma Labs has filed the application
Arch Pharma Labs has filed the application
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
